# EDGAR Filing Document

**Accession Number:** 0001607962
**File Stem:** 0001178913-26-000081
**Filing Date:** 2026-1
**Character Count:** 6429
**Document Hash:** 78082ab212cbf4a0e97a603d585d5da0
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001178913-26-000081.hdr.sgml**: 20260106

**ACCESSION NUMBER**: 0001178913-26-000081

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20260106

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**FILED AS OF DATE**: 20260106

**DATE AS OF CHANGE**: 20260106

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Lifeward Ltd.
- **CENTRAL INDEX KEY:** 0001607962
- **STANDARD INDUSTRIAL CLASSIFICATION:** ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 000000000
- **STATE OF INCORPORATION:** L3
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36612
- **FILM NUMBER:** 26511690

**BUSINESS ADDRESS:**
- **STREET 1:** 200 DONALD LYNCH BLVD.
- **CITY:** MARLBOROUGH
- **STATE:** MA
- **ZIP:** 01752
- **BUSINESS PHONE:** 15082511154

**MAIL ADDRESS:**
- **STREET 1:** 200 DONALD LYNCH BLVD.
- **CITY:** MARLBOROUGH
- **STATE:** MA
- **ZIP:** 01752

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ReWalk Robotics Ltd.
- **DATE OF NAME CHANGE:** 20140620

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Argo Medical Technologies Ltd.
- **DATE OF NAME CHANGE:** 20140513

?xml version='1.0' encoding='ASCII'?

------

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### Washington, D.C. 20549

### FORM 8-K

#### CURRENT REPORT

#### Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): <u>January 6, 2026</u>

Lifeward Ltd.

------

(Exact name of registrant as specified in its charter)

<u> Israel </u> <u> 001-36612 </u> <u> Not applicable </u> <br> (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.)

<u> 200 Donald Lynch Blvd., Marlborough MA </u> <u> 01752 </u> <br> (Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: <u>+508.251.1154</u> 

Not applicable<br>

(Former name or former address, if changed since last report)

**Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

#### Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class  | Trading Symbol(s) | Name of each exchange on which registered |
| Ordinary shares, par value NIS 1.75  | LFWD  | Nasdaq Capital Market  |

---

**

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

---

| | |
|:---|:---|
| **Item 5.07** | **Submission of Matters to a Vote of Security Holders.** |

---

On January 6, 2026, Lifeward Ltd. (the "Company") held its Extraordinary General Meeting of Shareholders (the "Meeting"). An aggregate of 7,620,593 ordinary shares, par value NIS 1.75 each, of Lifeward Ltd. (the "Company"), or approximately 41.7% of the 18,293,776 ordinary shares issued and outstanding as of November 26, 2025, the record date for the Meeting, were present or voted at the Meeting, constituting a quorum. The following proposals were voted upon at the Meeting, with the results of such voting as set forth below. Proposals No. 1, 2 and 3 received the requisite level of approval by shareholders. The proposals are described in greater detail in the Company's Definitive Proxy Statement on Schedule 14A, filed with the Securities and Exchange Commission on December 1, 2025, for the Meeting.

#### Results of the Meeting
***Proposal No. 1:*** To authorize the Board of Directors of the Company (the "Board") to determine whether to effect a reverse share split of the Company's outstanding ordinary shares, par value NIS 1.75 each, and if so, to set a ratio within a range of 1-for-2 to 1-for-12, to be effective on a date to be determined by the Board, and to approve conforming amendments to the Company's Seventh Amended and Restated Articles of Association to reflect any such reverse share split.

---

| | | | |
|:---|:---|:---|:---|
| **<u>For</u>** | **<u>Against</u>** | **<u>Abstain</u>** | **<u>Broker Non-Votes</u>** |
| 5,473,874 | 2,084,129 | 62,589 | 0 |

---

***Proposal No. 2:*** Subject to the approval of Proposal 1, and if the Board determines to effect a reverse share split pursuant thereto, to approve amendments to the Company's Seventh Amended and Restated Articles of Association authorizing an increase in the Company's authorized share capital.

---

| | | | |
|:---|:---|:---|:---|
| **<u>For</u>** | **<u>Against</u>** | **<u>Abstain</u>** | **<u>Broker Non-Votes</u>** |
| 5,343,641 | 2,149,990 | 126,960 | 0 |

---

***Proposal No. 3:*** To amend the Company's Seventh Amended and Restated Articles of Association to eliminate the par value of the Company's ordinary shares.

---

| | | | |
|:---|:---|:---|:---|
| **<u>For</u>** | **<u>Against</u>** | **<u>Abstain</u>** | **<u>Broker Non-Votes</u>** |
| 5,037,563 | 1,506,673 | 1,076,355 | 0 |

---

------

#### SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | |
|:---|:---|
| **Lifeward Ltd.** | **Lifeward Ltd.** |
| By: | /s/ Mark Grant |
| Name: | Mark Grant |
| Title: | President and Chief Executive Officer |

---

Dated: January 6, 2026

------